stockrowXencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Free cash flow
Xencor, Inc.'s free cash flow for fiscal 2025 was −$138.3M, compared with −$211.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$208.3M. Over the past ten years it has ranged from −$211.7M (fiscal 2024) to $92.2M (fiscal 2016); the current reading is higher than 18% of that period. Xencor, Inc. ranks 542nd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$138.3M | — |
| FY2024 | −$211.7M | — |
| FY2023 | −$99.2M | — |
| FY2022 | −$18.9M | — |
| FY2021 | −$32.8M | — |
| FY2020 | −$18.8M | — |
| FY2019 | $53.3M | — |
| FY2018 | −$88.9M | — |
| FY2017 | −$40.9M | — |
| FY2016 | $92.2M | 301.00% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$56.2M | — |
| Mar 2026 | −$68.2M | — |
| Dec 2025 | −$52.9M | — |
| Sep 2025 | −$31.0M | — |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ADMA ADMA Biologics Inc compare | $140.5M |
| MBX MBX Biosciences, Inc. compare | −$85.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.9M |
| PHVS Pharvaris N.V. compare | −$178.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$196.9M |
| XNCR Xencor, Inc. | −$208.3M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$314.5M |
| BEAM Beam Therapeutics Inc. compare | −$398.2M |
| RCUS Arcus Biosciences, Inc. compare | −$465.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement